Pittsburgh, PA – According to filings with the U.S. Securities and Exchange Commission, Noveome Biotherapeutics is raising $15,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, William Golden played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Noveome Biotherapeutics

Noveome is a clinical-stage biopharmaceutical company advancing ST266ù a first-of-its-kind, multi-targeted secretome containing hundreds of biologically active proteins and other factors crucial to neuroprotection, the modulation of inflammation, cell recovery and healing. Noveome received seed funding and access to world-class researchers, physicians and experts in private and public reimbursement at Pittsburgh’s leading healthcare institutions, including UPMC Health System, Highmark Blue Cross/Blue Shield, the University of Pittsburgh and Carnegie Mellon University. We are passionate about helping the Pittsburgh region grow into the world’s next great nexus for biotechnology.

To learn more about Noveome Biotherapeutics, visit http://www.noveome.com/

Contact:
William Golden, Chief Executive Officer
412-402-9914
https://www.linkedin.com/in/william-golden-592710170/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved